Opinion|Videos|July 24, 2024
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on overall survival from the
CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC. - What are your key takeaways from this study?
- How do you think the long term follow up data supports decision-making in metastatic NSCLC?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
5